The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Alimta     (2R)-2-[[4-[2-(4-amino-2-oxo- 3,5,7...

Synonyms: SureCN7969, CHEMBL59843, Alimta (TN), CHEMBL225072, Bio-0078, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of HSDB 7316

 

High impact information on HSDB 7316

 

Chemical compound and disease context of HSDB 7316

 

Biological context of HSDB 7316

 

Anatomical context of HSDB 7316

 

Associations of HSDB 7316 with other chemical compounds

 

Gene context of HSDB 7316

 

Analytical, diagnostic and therapeutic context of HSDB 7316

References

  1. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, n.u.l.l., Manegold, C., Paul, S., Paoletti, P., Einhorn, L., Bunn, P.A. J. Clin. Oncol. (2004) [Pubmed]
  2. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. Scagliotti, G.V., Shin, D.M., Kindler, H.L., Vasconcelles, M.J., Keppler, U., Manegold, C., Burris, H., Gatzemeier, U., Blatter, J., Symanowski, J.T., Rusthoven, J.J. J. Clin. Oncol. (2003) [Pubmed]
  3. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. Castro, M. J. Clin. Oncol. (2003) [Pubmed]
  4. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Gomez, H.L., Santillana, S.L., Vallejos, C.S., Velarde, R., Sanchez, J., Wang, X., Bauer, N.L., Hockett, R.D., Chen, V.J., Niyikiza, C., Hanauske, A.R. Clin. Cancer Res. (2006) [Pubmed]
  5. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Li, Q., Yano, S., Ogino, H., Wang, W., Uehara, H., Nishioka, Y., Sone, S. Clin. Cancer Res. (2007) [Pubmed]
  6. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway. Zhao, R., Hanscom, M., Chattopadhyay, S., Goldman, I.D. Cancer Res. (2004) [Pubmed]
  7. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Wang, Y., Zhao, R., Chattopadhyay, S., Goldman, I.D. Cancer Res. (2002) [Pubmed]
  8. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. Hughes, A., Calvert, P., Azzabi, A., Plummer, R., Johnson, R., Rusthoven, J., Griffin, M., Fishwick, K., Boddy, A.V., Verrill, M., Calvert, H. J. Clin. Oncol. (2002) [Pubmed]
  9. A phase I study of pemetrexed, Carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Seiwert, T.Y., Connell, P.P., Mauer, A.M., Hoffman, P.C., George, C.M., Szeto, L., Salgia, R., Posther, K.E., Nguyen, B., Haraf, D.J., Vokes, E.E. Clin. Cancer Res. (2007) [Pubmed]
  10. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Vogelzang, N.J., Rusthoven, J.J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., Niyikiza, C., Paoletti, P. J. Clin. Oncol. (2003) [Pubmed]
  11. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Giovannetti, E., Mey, V., Nannizzi, S., Pasqualetti, G., Marini, L., Del Tacca, M., Danesi, R. Mol. Pharmacol. (2005) [Pubmed]
  12. Pemetrexed in malignant pleural mesothelioma. Hazarika, M., White, R.M., Booth, B.P., Wang, Y.C., Ham, D.Y., Liang, C.Y., Rahman, A., Gobburu, J.V., Li, N., Sridhara, R., Morse, D.E., Lostritto, R., Garvey, P., Johnson, J.R., Pazdur, R. Clin. Cancer Res. (2005) [Pubmed]
  13. A Phase I Study of Pemetrexed (ALIMTA) and Cyclophosphamide in Patients with Locally Advanced or Metastatic Breast Cancer. Dittrich, C., Petruzelka, L., Vodvarka, P., Gneist, M., Janku, F., Kysela, T., Melemed, A., Latz, J., Simms, L., Krejcy, K. Clin. Cancer Res. (2006) [Pubmed]
  14. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer. Hensley, M.L., Larkin, J., Fury, M., Gerst, S., Tai, D.F., Sabbatini, P., Konner, J., Orlando, M., Goss, T.L., Aghajanian, C.A. Clin. Cancer Res. (2008) [Pubmed]
  15. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Sweeney, C.J., Takimoto, C.H., Latz, J.E., Baker, S.D., Murry, D.J., Krull, J.H., Fife, K., Battiato, L., Cleverly, A., Chaudhary, A.K., Chaudhuri, T., Sandler, A., Mita, A.C., Rowinsky, E.K. Clin. Cancer Res. (2006) [Pubmed]
  16. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Rowinsky, E.K., Beeram, M., Hammond, L.A., Schwartz, G., De Bono, J., Forouzesh, B., Chu, Q., Latz, J.E., Hong, S., John, W., Nguyen, B. Clin. Cancer Res. (2007) [Pubmed]
  17. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Giovannetti, E., Mey, V., Danesi, R., Mosca, I., Del Tacca, M. Clin. Cancer Res. (2004) [Pubmed]
  18. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Ramirez, J.M., Ocio, E.M., San Miguel, J.F., Pandiella, A. Leukemia (2007) [Pubmed]
  19. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. von der Maase, H., Lehmann, J., Gravis, G., Joensuu, H., Geertsen, P., Gough, J., Chen, G., Kania, M. Ann. Oncol. (2006) [Pubmed]
  20. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Bischof, M., Weber, K.J., Blatter, J., Wannenmacher, M., Latz, D. Int. J. Radiat. Oncol. Biol. Phys. (2002) [Pubmed]
  21. Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier. Zhao, R., Chattopadhyay, S., Hanscom, M., Goldman, I.D. Clin. Cancer Res. (2004) [Pubmed]
  22. Phase I trials of pemetrexed. Fossella, F.V., Gatzemeier, U. Semin. Oncol. (2002) [Pubmed]
  23. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line. Wang, Y., Zhao, R., Goldman, I.D. Biochem. Pharmacol. (2003) [Pubmed]
  24. Molecular basis of antifolate resistance. Assaraf, Y.G. Cancer Metastasis Rev. (2007) [Pubmed]
  25. Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene. Capiaux, G.M., Budak-Alpdogan, T., Alpdogan, O., Bornmann, W., Takebe, N., Banerjee, D., Maley, F., Bertino, J.R. Cancer Gene Ther. (2004) [Pubmed]
  26. Cytotoxic effects of pemetrexed in gastric cancer cells. Kim, J.H., Lee, K.W., Jung, Y., Kim, T.Y., Ham, H.S., Jong, H.S., Jung, K.H., Im, S.A., Kim, T.Y., Kim, N.K., Bang, Y.J. Cancer Sci. (2005) [Pubmed]
  27. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Sigmond, J., Backus, H.H., Wouters, D., Temmink, O.H., Jansen, G., Peters, G.J. Biochem. Pharmacol. (2003) [Pubmed]
  28. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Bischof, M., Abdollahi, A., Gong, P., Stoffregen, C., Lipson, K.E., Debus, J.U., Weber, K.J., Huber, P.E. Int. J. Radiat. Oncol. Biol. Phys. (2004) [Pubmed]
  29. Distribution of the novel antifolate pemetrexed to the brain. Dai, H., Chen, Y., Elmquist, W.F. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  30. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Govindan, R., Garfield, D.H. Semin. Oncol. (2004) [Pubmed]
  31. Chemotherapy for metastatic or unresectable bladder cancer. Bellmunt, J., Albiol, S. Semin. Oncol. (2007) [Pubmed]
 
WikiGenes - Universities